Summer Sale

Up to 30% off — ends 7 Aug

ONLY00h00m00s

Get 30% Off

Up to 30% off — ends 7 Aug

ONLY00h00m00s

Gurdeep Sagoo

Senior Lecturer in Health Economics

Newcastle University

United Kingdom

Has grant

This profile is automatically generated from trusted academic sources.

Google Scholar

ORCID

How do I reach out?

Meet Kite AI

Contact this professor

ORCID

Google Scholar

Research Interests

Pharmacotherapy

30%

Health Economics

80%

Polypharmacy

20%

Maternity Care

20%

Medical Science

20%

Machine Learning In Healthcare

20%

Drug Repurposing

20%

Ask ApplyKite AI

Start chatting

How can you help me contact this professor?

What are this professor's research interests?

How should I write an email to this professor?

Recent Grants

Grant: Close

University of Leeds Technology Specific Evaluation Team - TSET

Open Date: 2022-01-01

Close Date: 2023-03-01

Grant: Close

DOLCE: Determining the impact of Optellum's Lung Cancer Prediction (LCP) artificial intelligence solution for lung nodule risk stratification on service utilisation, health economics, and patient outcomes.

Open Date: 2021-07-01

Close Date: 2024-06-01

Grant: Close

Biologics in refractory vasculitis (BIOVAS): A pragmatic randomised double-blind placebo-controlled modified-crossover trial of biologic therapy for refractory primary non-ANCA associated vasculitis in adults and children

Open Date: 2019-09-01

Close Date: 2025-02-28

Grant: Close

Deep learning mammography: Artificial intelligence for breast screening (Khieron MIA)GB

Open Date: 2019-01-01

Close Date: 2020-12-01

Gurdeep Sagoo

Senior Lecturer in Health Economics

How do I reach out?

Contact this professor

Research Interests

Ask ApplyKite AI

Recent Grants

Articles22

OSAIRIS: Lessons Learned From the Hospital-Based Implementation and Evaluation of an Open-Source Deep-Learning Model for Radiotherapy Image Segmentation

Machine Learning in Health Economic Evaluations: Protocol for a Scoping Review

Uncertainty in Matching-Adjusted Indirect Comparisons Using Real-World Evidence: Evidence Assessment Group Perspective

Cost-effectiveness of companion BRCA testing and adjuvant olaparib treatment in patients with BRCA-mutated high-risk HER2-negative early breast cancer.

NICE Approaches to Expert Opinion Evidence in Highly Specialised Technologies: Time to Change? Evidence Assessment Group Perspective

Proportion of Antipsychotics with CYP2D6 Pharmacogenetic (PGx) Associations Prescribed in an Early Intervention in Psychosis (EIP) Cohort: A Cross-Sectional Study.

Determining the impact of an artificial intelligence tool on the management of pulmonary nodules detected incidentally on CT (DOLCE) study protocol: a prospective, non-interventional multicentre UK study.

Reporting Standards for Economic Evaluations of Artificial Intelligence (AI) Interventions: A CHEERS Extension

Evaluating high-cost technologies - no need to throw the baby out with the bathwater.

Cost-effectiveness of decellularised bone allograft compared with fresh-frozen bone allograft for acetabular impaction bone grafting during a revision hip arthroplasty in the UK

Cost-effectiveness requirements for implementing artificial intelligence technology in the Women’s UK Breast Cancer Screening service

Learning from parental experience in a neonatal surgical unit: a qualitative service evaluation.

Developing a method to capture parental experience in a neonatal surgical centre in the context of COVID-19: A qualitative study

We must start using pharmacogenomic information tooptimise medicines for older people

What Are the Barriers and Enablers to the Implementation of Pharmacogenetic Testing in Mental Health Care Settings?

Cost analysis of managing B3 breast lesions by vacuum excision at Leeds Breast Unit using a decision model

The cost-effectiveness of using rapid diagnostic tests for the diagnosis of typhoid fever in patients with suspected typhoid fever: a systematic review.

Cost‐effectiveness analysis of telephone‐based cognitive behaviour therapy compared to treatment as usual CBT for cancer patients: Evidence from a small, randomised controlled trial

An Analysis of Pharmacogenomic-Guided Pathways and Their Effect on Medication Changes and Hospital Admissions: A Systematic Review and Meta-Analysis.

The DANTE trial protocol: a randomised phase III trial to evaluate the Duration of ANti-PD-1 monoclonal antibody Treatment in patients with metastatic mElanoma.

Early economic evaluation of an intervention to improve uptake of the NHS England Diabetes Prevention Programme.

Cost-effectiveness of a new autoantibody test added to Computed Tomography (CT) compared to CT surveillance alone in the diagnosis of lung cancer amongst patients with indeterminate pulmonary nodules.

Collaborators13

Tom Griffiths

Greg Bristow

Edward Meinert

Samantha McLean

Christian Ottensmeier

Nahel Yaziji

Andrew Robinson

David Wong

Eleanor Bryant

Samuel N Frempong

Stephen Rice

Sheila Wallace

Luke Vale

How do I reach out?